Safety Study of Mesenchymal Precursor Cells in Type 2 Diabetes

Completed · Phase 1/Phase 2

Conditions studied: Type 2 Diabetes

In brief

This study is being conducted to assess the overall safety and tolerability of a single intravenous infusion of three doses of Mesenchymal Precursor Cells versus Placebo in subjects with Type 2 Diabetes inadequately controlled on Metformin.

Key facts

Study ID
NCT01576328
Run by
Mesoblast, Ltd.
People needed
61
Starts
2012-04-01
Expected to finish
2015-10-01
Last updated by the study team
2020-06-02

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.